Oct 14, 2025
Buchholz Lab awarded federal grant to translate CRISPR technology towards innovative cancer research
The research group of Prof. Dr. Frank Buchholz is thrilled to announce the successful acquisition of a grant for the project "CanCorrect," aimed at revolutionizing cancer research, diagnostics, and therapy through advanced CRISPR technology.
The project – funded by the German Federal Ministry of Research, Technology and Space – focuses on developing optimized Adenine Base Editors (ABEs) for precise genome editing in cancer cells. Preliminary results show promising potential in correcting specific mutations and inhibiting tumor growth without adverse side effects.
With this grant, the research group will conduct further experiments to validate the efficacy and safety of ABE systems to correct cancer hotspot mutations. This, in turn, can lead to significant advancements in personalized cancer therapy and precision medicine, as it promises more precise diagnoses and opens new therapeutic avenues for cancer patients. This technology could pave the way for innovative, tailored cancer treatments and significantly advance the clinical implementation of genome editing.